The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
15-Dec-19
$45.4 billion
Target:
Nutrition & Biosciences Division of DuPont de Nemours, Inc.
Acquiror:
International Flavors and Fragrances, Inc.
Advising IFF, a global leader in flavors and fragrances, on its merger with DuPont’s Nutrition & Biosciences Division, creating a clear global leader in the specialty ingredients sector
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
30-Mar-07
$24.4 billion
Target:
Alliance Boots plc
Acquiror:
Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
Advised Alliance Boots plc, the leading international pharmacy-led health and beauty group, on a proposal regarding an offer for the company from a consortium comprising of Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
25-Feb-10
$14.4 billion
Target:
Coca-Cola Enterprises Inc.
Acquiror:
The Coca-Cola Company
Advised the Affiliated Transaction Committee of Coca-Cola Enterprises Inc. on the sale of its North American bottling operations to The Coca-Cola Company and on its concurrent acquisition of The Coca-Cola Company’s bottling operations in the Nordic region
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
16-Jan-01
$11.5 billion
Target:
Ralston Purina Co.
Acquiror:
Nestlé S.A.
Advised Nestlé on the agreed cash offer for the US pet-food company Ralston Purina
09-Mar-20
$10.6 billion
Target:
Tesco plc’s Thailand and Malaysia businesses
Acquiror:
Charoen Pokphand Group
Advised Tesco plc, a leading UK retailer, on the sale of its Thailand and Malaysia businesses to Charoen Pokphand Group, the Thai conglomerate
17-Jul-00
$10.5 billion
Target:
Diageo plc
Acquiror:
General Mills, Inc.
Advised Diageo on the sale of The Pillsbury Company for $5.1 billion in assumed debt and $5.4 billion in stock to General Mills.
06-Mar-14
$10.0 billion
Target:
Safeway Inc.
Acquiror:
Albertsons (majority owned by Cerberus Capital Management)
Advised the Board of Directors of Safeway Inc., a leading food and drug retailer, on its acquisition by Albertsons
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
20-Aug-12
$7.3 billion
Target:
Coventry Health Care Inc.
Acquiror:
Aetna
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
07-May-18
$7.1 billion
Target:
Frutarom
Acquiror:
International Flavors and Fragrances
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
18-Mar-03
$7.0 billion
Target:
Wella AG
Acquiror:
The Procter & Gamble Company
Advised Wella AG, a global market leader in hair care and fragrances, on its sale to The Procter & Gamble Company
12-Jun-08
$6.7 billion
Target:
Applied Biosystems Group
Acquiror:
Invitrogen Corporation
Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems
23-Oct-12
$5.7 billion
Target:
Target Corporation’s REDcard credit card assets
Acquiror:
The Toronto-Dominion Bank Group
Advised The Toronto-Dominion Bank Group on its acquisition of Target Corporation’s REDcard credit card assets
23-Apr-09
$5.7 billion
Target:
Lion Nathan
Acquiror:
Kirin Holdings
Advised Lion Nathan, a leading brewery in Australia, on the sale of its remaining 54% stake to Kirin Holdings, a leading beverage company in Japan
18-Apr-19
$4.8 billion
Target:
Acreage Holdings Inc.
Acquiror:
Canopy Growth Corporation
Advised Canopy Growth, a leading diversified cannabis company, on its acquisition of Acreage Holdings Inc., a vertically-integrated multi-state cannabis company with its headquarters in New York
06-Nov-06
$4.2 billion
Target:
Kos Pharmaceuticals, Inc.
Acquiror:
Abbott Laboratories
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories
03-Dec-18
$4.0 billion
Target:
Assets owned by GlaxoSmithKline plc
Acquiror:
Unilever plc / Hindustan Unilever Limited
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment